SABS · SAB Biotherapeutics, Inc.

This Master Manufacturing Services Agreement represents a critical strategic milestone for SAB Biotherapeutics, as it secures dedicated, cGMP-compliant clinical and commercial manufacturing capacity for its lead candidate SAB-142 — a development-stage therapeutic whose regulatory and commercial viability hinges on reliable, scalable production. The five-year term tied explicitly to FDA approval underscores the agreement’s contingent, milestone-driven nature: no minimum spend obligation accrues until regulatory authorization is obtained, mitigating near-term financial exposure while locking in long-term supply assurance. The $36 million minimum aggregate spend post-approval signals meaningful commercial commitment and provides Emergent with revenue visibility, but also imposes substantial execution risk on SAB BIO — failure to achieve or sustain commercial demand could trigger significant termination liabilities. The exclusivity clause strengthens supply chain control but introduces single-point dependency; although SAB BIO retains the right to qualify an alternative manufacturer, the narrow conditions for using that source — limited to instances where Emergent is 'unable or declines' to manufacture — preserve Emergent’s de facto operational leverage. The inclusion of pricing to be finalized via future amendment (including batch price and annual adjustments) defers key commercial terms, leaving cost structure and margin implications undetermined. For investors, this agreement reduces technical manufacturing risk but heightens regulatory and commercial execution risk — success now depends less on process capability and more on timely FDA approval and subsequent market uptake of SAB-142.